CADTH Canadian Drug Expert Committee final recommendation: Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.) indication : type 2 diabetes mellitus
The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin and metformin hydrochloride (empagliflozin/metformin) fixed-dose combination (FDC) be reimbursed for patients with type 2 diabetes mellitus
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, October 25, 2016
|
| Series: | Common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin and metformin hydrochloride (empagliflozin/metformin) fixed-dose combination (FDC) be reimbursed for patients with type 2 diabetes mellitus |
|---|---|
| Physical Description: | 1 PDF file (5 pages) |